Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Diagnostics
MedTech
DNA and RNA testing helps identify blood cancer relapse risks
Researchers have found a dual genetic test is more accurate in identifying relapse risks for certain patients with blood cancer.
Ben Adams
Oct 13, 2025 10:00am
Navidea Biopharmaceuticals files for Chapter 11
Oct 10, 2025 8:10am
Thermo Fisher launches biopsy test to assess lung rejection risk
Oct 9, 2025 10:50am
Oxford BioDynamics unveils new target use for EpiSwitch test
Oct 8, 2025 2:34pm
Alpenglow teams up with Virdx to boost prostate cancer diagnosis
Oct 8, 2025 9:20am
Lilly calls for improvements to Alzheimer's testing in Europe
Oct 7, 2025 9:30am
